A clinic's GLP-1 ads can name the service and the visit, but several claims owners are tempted to add are exactly the ones the official pages put in doubt. This is a claim-by-claim review built only from pages I read on 2026-10-15; I am not a lawyer, and this post is not legal advice.
Quick answer
Write the ad about the consultation and the clinician, not about the drug being the same as, or as good as, a brand. Do not call a compounded drug FDA-approved, because FDA says it is not. Treat every number of pounds, every photo and every patient quote as a claim you must be able to support. Bidding on "semaglutide near me", at an average $30.19 a click in Google Ads Keyword Planner estimates for the US, October 2026 (national context, not what you will pay), needs Google certification because the keyword names a drug. Before any of that spend, have a lawyer read the final ad and your state medical board's rules.
Which claims are risky, and what do the pages say?
The last column is my reading of the source, not a legal opinion. Where the pages I read are silent, I say so.
| Claim in the ad | What the source says | My reading |
|---|---|---|
| "FDA-approved" about a compounded drug | FDA: "compounded drugs are not FDA approved" (FDA, checked 2026-10-15) | Do not use |
| "Same active ingredient as Ozempic" or "the same as" a brand | FDA lists a company that "makes claims such as the compounded drug is the same as an FDA-approved drug" among its warning signs (same page) | Avoid; ask counsel |
| Naming semaglutide or tirzepatide in ad text | Both are on Google's prescription drug terms list (Google, checked 2026-10-15); US ads and landing pages may use them, keyword-targeting them needs certification (Google, checked 2026-10-15) | Allowed in text; keywords need certification |
| "Lose 20 pounds in 8 weeks" | FTC: health claims need "competent and reliable scientific evidence" (FTC, checked 2026-10-15); Meta bars clickbait such as promises of specific outcomes within a set timeframe without disclaimers or qualifiers (Meta, checked 2026-10-15) | Depends on your evidence |
| Before-and-after photos | FTC: such images can convey a claim. Meta: the current page no longer bars side-by-side weight loss comparisons, as its December 2024 version did | Depends; recheck Meta |
| Patient testimonials | 16 CFR 255.2: an endorsement is likely read as typical, and "Results not typical" is called insufficient (eCFR, checked 2026-10-15) | Depends; disclose what is typical; barred for Ontario physicians (below) |
| A monthly price | None of the pages I read bans one; FDA's consumer red flags include "prices that seem too good to be true", and Canada's drug regulation allows price and quantity (below) | Not banned; keep it accurate |
| "No prescription needed" | Google: "Offering prescription drugs without a prescription is not allowed" (Google, checked 2026-10-15); FDA's red flags include no screening and prescription by a licensed doctor | Not allowed |
| Prescribing through telehealth | Google (US): LegitScript plus Google certification. Meta: LegitScript plus Meta's authorization to promote a drug; none for telehealth services in general | Certification first if a drug is promoted |
What did FDA say about compounded GLP-1 drugs?
The FDA page I read, marked current as of 10/01/2026, says compounded drugs are not FDA approved and that FDA does not review them for safety, effectiveness or quality before they are marketed (FDA, checked 2026-10-15). It says FDA has sent warning letters over illegally marketed semaglutide and tirzepatide sold online, and has warned telehealth companies for marketing unapproved drugs such as retatrutide. It also says salt forms such as semaglutide sodium are different active ingredients from those in the approved drugs, and that FDA knows of no lawful basis for compounding with them.
The shortage history matters because FDA ties the compounding of copies to it: once a shortage is resolved, FDA generally considers the drug commercially available. FDA determined the tirzepatide injection shortage resolved on December 19, 2024, and the semaglutide injection shortage on February 21, 2025 (FDA, checked 2026-10-15). The wind-down periods it gave compounders have ended, and its April 1, 2026 update says neither drug currently appears on the shortage list or the 503B bulks list (bulk ingredients outsourcing facilities may compound from).
Even during those periods, FDA said it may still act on violations not tied to the shortage list. So ask your compounding pharmacy in writing what its legal basis is today, and have a lawyer read the answer before any ad mentions a compounded drug.
Does the FTC care what a weight-loss ad promises?
Yes, and its test does not depend on the platform. The FTC's Health Products Compliance Guidance (business guidance, not law, by its own words) says health claims need competent and reliable scientific evidence (FTC, checked 2026-10-15). It adds that an honest testimonial is not enough on its own, and that testimonials reporting results more dramatic than users can generally expect are likely to be deceptive.
Its weight-loss example is a supplement ad with before-and-after photos of a woman who says she lost 16 pounds in eight weeks. The FTC calls the fine-print note "These results are not typical" too vague, because a well-conducted trial showed an average loss of only four pounds over placebo. The Endorsement Guides, 16 CFR 255.2, point the same way: when the advertiser cannot show that an endorser's experience is what consumers generally achieve, the ad should clearly disclose the generally expected result (eCFR, checked 2026-10-15).
For each testimonial you run, decide what a typical patient on your program actually gets, and whether you can show it. If you cannot, the quote does not belong in the ad. In Canada the matching rule sits in the Competition Act, under which a public statement on how well a product works that is "not based on an adequate and proper test thereof" is reviewable conduct, with the proof on whoever makes it (Justice Laws Website, checked 2026-10-15).
What do Google and Meta add?
My med spa marketing post covers how Google certification works for a practice, so I add only two points. In its US section, Google allows telemedicine providers if they are accredited by LegitScript's Healthcare Merchant Certification Program and also certified with Google (Google, checked 2026-10-15), and it treats restricted drug terms as a sensitive interest category in which advertiser-curated audiences such as Customer Match, your data segments and lookalike segments can't be used (Google, checked 2026-10-15). An ad that promotes semaglutide or tirzepatide cannot be aimed at a list of your own site visitors or patients.
Meta says prescription drug ads need active LegitScript certification, Meta's authorization, a disclaimer to consult a licensed professional or get a valid prescription, and targeting limited to people 18 or older in the United States, Canada or New Zealand where the advertiser is certified (Meta, checked 2026-10-15). It also says advertisers do not need written authorization for ads that promote telehealth services generally. Its health and wellness page requires weight loss ads to target people 18 or older and sends prescription weight loss products to the drugs policy (Meta, checked 2026-10-15).
An ad for medical weight loss consultations that names no drug sits under the health and wellness rules, while one promoting a prescription drug takes the certification route. Meta's review decides which one yours is, so submit a single ad before a whole campaign depends on it.
What changes in Canada, and with my state board?
In Canada, section C.01.044 of the Food and Drug Regulations says that a person who advertises a prescription drug to the general public "shall not make any representation other than with respect to the brand name, the proper name, the common name and the price and quantity of the drug" (Justice Laws Website, checked 2026-10-15). A Canadian ad about semaglutide or tirzepatide may state those five things about the drug and nothing else. Ontario's physician regulator, the CPSO, bars testimonials and "any reference to a specific drug, appliance or equipment" from physician advertising and attaches its own conditions to before-and-after photos (CPSO, checked 2026-10-15). Each province's college has its own policy, so have counsel check the wording against it and the regulation.
In the US, every state medical board writes its own advertising rules for physicians. I did not review any of them for this post, so read yours before the ad goes live.
How do I tell which ads bring patients who stay?
A lead is the cheapest thing to buy and the least useful number. Count four steps in your own scheduling and billing system: consult booked, prescribed, started, and still on the program at a later month you choose. Divide the month's spend by the last two.
Illustrative: every number below is made up for an imaginary weight loss clinic, and none comes from a client.
| Campaign A | Campaign B | |
|---|---|---|
| Spend | $6,000 | $6,000 |
| Leads (calls and forms) | 150 | 240 |
| Cost per lead | $40 | $25 |
| Patients who started | 30 | 20 |
| Cost per started patient | $200 | $300 |
| Still on the program at month 3 | 18 | 6 |
| Cost per patient still on program | $333 | $1,000 |
Campaign B looks cheaper per lead and is three times as expensive per retained patient ($6,000 / 6 = $1,000 against $6,000 / 18 = $333). The formula to repeat: spend divided by patients who reached the step you care about.
The ad platform needs only a signal to learn from: I send a booked or paid event with a dollar value and no condition, drug or visit reason, and keep the started and retained counts out of it. My boundary for that is in HIPAA-conscious conversion tracking. From October 2023 to September 2025 I bought media on Google Ads and Meta Ads, nearly $700K in cumulative spend, but none of it for GLP-1 or weight loss advertisers, so read this part as a setup plan, not a track record.
What should I ask whoever writes the ads?
- Who reviewed the ad wording for FDA, FTC and state board rules, and is that review in writing?
- Does any ad say "FDA-approved", "same as" a brand drug, or promise pounds in a time frame, and what is the evidence for it?
- Are patient photos and quotes typical, and where is the typical result disclosed?
- Which accounts hold LegitScript, Google and Meta authorization, and in whose name?
- Is any remarketing or Customer Match list built from weight loss visitors?
- Will the report show started and retained patients, not only leads? How to compare healthcare agency proposals has a scorecard for the rest.
Tags
Frequently asked questions
Can I say my compounded semaglutide is the same as Ozempic?
I would not. FDA's page on unapproved GLP-1 drugs lists a seller claiming the compounded drug is the same as an FDA-approved drug as a warning sign for consumers. Describe what you actually prescribe and who compounds it, and let a lawyer check the wording.
Do I need LegitScript to run GLP-1 ads?
It depends on what the ad promotes. Google's US rules say telemedicine providers must be accredited by LegitScript and certified with Google, and Meta requires active LegitScript certification plus its own authorization to promote prescription drugs. Meta also says advertisers do not need written authorization to promote telehealth services generally, so what the ad names matters.
Can my weight loss ads show a patient's before-and-after photos?
Meta's health and wellness page, last changed on July 22, 2026, no longer has the line from its December 2024 version that barred side-by-side weight loss comparisons, and it sends prescription weight loss products to its drugs policy, which says nothing about photos. The FTC guidance treats before-and-after images as a claim that needs support and calls a vague note such as 'These results are not typical' not enough. Recheck Meta's page the day you build the ad.
Is the GLP-1 shortage still on?
On the FDA page I read, semaglutide injection's shortage was declared resolved on February 21, 2025, and tirzepatide's on December 19, 2024. The same page says that as of April 1, 2026 neither drug is on the shortage list or the 503B bulks list. That is why the compounded versions are the part of your ads that deserves a second look.
What should my ad platform be told about a GLP-1 patient?
A booked or paid event with a dollar value, and nothing that names the condition, the drug or the visit reason. Count who started and who is still on the program inside your own system and compare it with ad spend yourself. The tracking boundary I use is described in my post on HIPAA-conscious conversion tracking.
Written by
Alexander Cheberko
Marketing Analytics & Conversion Tracking Engineer, US and Canada, run remotely
- Media buyer on Google Ads and Meta Ads from October 2023 to September 2025, nearly $700K in spend.
- Set up patient conversion tracking for a New York medical practice (anonymized).
- Upwork Top Rated, 5.0 from 20 reviews.